XTL Biopharmaceuticals Ltd. Logo

XTL Biopharmaceuticals Ltd.

Clinical-stage biopharmaceutical company developing drugs for autoimmune diseases.

XTLB | TA

Overview

Corporate Details

ISIN(s):
IL0010854979
LEI:
529900NDDXEAPTUTXP41
Country:
Israel
Address:
5 HaCharoshet St., 4365603 Raanana

Description

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-08-10 18:51
XTL-financial results for the six months ended June 30, 2023
English 36.0 KB
2023-05-17 00:55
Financial Overview for Three Months Ended March 31, 2023
English 142.5 KB
2023-05-17 00:55
Financial Overview for Three Months Ended March 31, 2023
English 36.1 KB
2023-03-22 15:24
Year ended December 31 ,2022 Results
English 731.3 KB
2023-03-22 15:24
Year ended December 31 ,2022 Results
English 36.0 KB
2023-03-03 09:23
Results of Meeting held on March 2, 2023
English 147.7 KB
2023-03-03 09:23
Results of Meeting held on March 2, 2023
English 35.9 KB
2023-03-03 09:22
Results of Meeting held on March 2, 2023
English 147.7 KB
2023-03-03 09:22
Results of Meeting held on March 2, 2023
English 35.9 KB
2023-02-24 02:02
deferred annual shareholders meeting will reconvene on March 02, 2023
English 112.0 KB
2023-02-24 02:02
deferred annual shareholders meeting will reconvene on March 02, 2023
English 140.6 KB
2023-02-01 20:12
Immediate Report of Meeting to be held on February 23, 23-Scribal error
English 812.1 KB
2023-02-01 20:12
Immediate Report of Meeting to be held on February 23, 23-Scribal error
English 685.6 KB
2023-02-01 20:12
Immediate Report of Meeting to be held on February 23, 23-Scribal error
English 137.7 KB
2023-01-21 22:37
NOTICE OF 2022 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 23…
English 1.1 MB

Automate Your Workflow. Get a real-time feed of all XTL Biopharmaceuticals Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for XTL Biopharmaceuticals Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for XTL Biopharmaceuticals Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.